EcuadorTuberculosis profile
Population  2014 16 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.47 (0.39–0.56) 2.9 (2.4–3.5)
Mortality (HIV+TB only) 0.31 (0.23–0.4) 1.9 (1.5–2.5)
Prevalence  (includes HIV+TB) 12 (6.4–20) 78 (40–127)
Incidence  (includes HIV+TB) 8.6 (6.3–11) 54 (39–71)
Incidence (HIV+TB only) 1.1 (0.82–1.5) 7.2 (5.2–9.6)
         
Case detection, all forms (%) 60 (46–82)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 4.9 (3.5–6.7) 26 (23–29)
MDR-TB cases among notified pulmonary
TB cases
200 (140–270) 120 (100–130)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 3 649   254
Pulmonary, clinically diagnosed 341   0
Extrapulmonary 913   0
       
Total new and relapse 5 157    
Previously treated, excluding relapses 195    
Total cases notified 5 352    
Among 5 157 new and relapse cases:
224 (4%) cases aged under 15 years; male:female ratio: 1.7
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 1 016 (28%) 720 (160%) 1 736
Laboratory-confirmed RR-/MDR-TB cases     451
Patients started on MDR-TB treatment ***     179
TB/HIV 2014 Number (%)
TB patients with known HIV status 4 729 (88)
HIV-positive TB patients 637 (13)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0 (0)
HIV-positive TB patients on antiretroviral therapy (ART) 637 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT 287  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (75) 5 277
Previously treated cases, excluding relapse, registered in 2013 (53) 197
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (54) 243
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 2.0
Culture (per 5 million population) 6.3
Drug susceptibility testing (per 5 million population) 0.3
Sites performing Xpert MTB/RIF 4
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 4.2
% Funded domestically 83%
% Funded internationally 17%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-04-30 Data: www.who.int/tb/data